Abstract

Idiopathic restless legs syndrome (RLS)—also known as Willis-Ekbom disease—is a neurological condition characterised by an overwhelming urge to move the legs, occurring during rest or inactivity, especially at night.^1-3 Symptoms are highly variable in frequency and severity, and can affect sleep and quality of life. First-line management includes addressing precipitating or aggravating factors and providing explanation, reassurance and advice on self-help strategies.^4-9 Drug therapy (e.g. a dopamine agonist) is used for patients with more severe symptoms.⁶ In December 2014, the marketing authorisation for a modified-release preparation containing oxycodone and naloxone (Targinact—Napp Pharmaceuticals) was expanded to include use in the treatment of severe to very severe RLS after failure of dopaminergic therapy.¹⁰ Here we review the management of adults with RLS, including the place of oxycodone/naloxone.